Proportion of patients vaccinated against influenza, pneumococcus, and herpes zoster before and after the 12-month intervention period. Values are n (%).
| Variables | Preintervention | Postintervention |
|---|---|---|
| Influenza, n = 102,101* | ||
| Ever received IVX | 92 (90.2) | 87 (86.1) |
| Received IVX in previous season | 81 (79.4) | 79 (78.2) |
| Pneumococcal, n = 1255† | ||
| Ever received any type of vaccine | 360 (28.7) | 575 (45.8) |
| PPSV23 only | 351 (28.0) | 293 (23.3) |
| PCV13 only | 5 (0.4) | 151 (12.0) |
| PPSV23 and PCV13 | 4 (0.3) | 131 (10.4) |
| No vaccine received, medical reason | 0 | 9 (0.7) |
| No vaccine received, patient reason | 2 (0.2) | 51 (4.1) |
| Herpes zoster, n = 1255† | ||
| Ever received vaccine | 32 (2.5) | 57 (4.5) |
| Prescription to receive elsewhere, no record of receipt | 0 | 28 (2.2) |
| No vaccine received, medical reason | 0 | 102 (8.1) |
| No vaccine received, patient reason | 0 | 46 (3.7) |
↵* Rates of IVX are based on self-report from a random sample of 102 patients who were interviewed for the study prior to implementation of the intervention and 101 who were interviewed after implementation of the intervention.
↵† Rates of pneumococcal and herpes zoster vaccination are based on electronic health record data for all eligible patients. IVX: influenza vaccine; PPSV23: 23-strain pneumococcal polysaccharide vaccine; PCV13: 13-strain pneumococcal conjugated vaccine.